. Author manuscript; available in PMC: 2010 Jun 1.

Published in final edited form as: Pharmacogenet Genomics. 2009 Jun;19(6):415–421. doi: 10.1097/FPC.0b013e32832a8e81

Table 2.

Main effect of FGB -455 variant on outcomes, n=30,076

Outcome	Total number of events		Event rate per 1000 person years		Main effect of genotype
	Total number of events		Event rate per 1000 person years		Minimally adjusted^*, Hazard Ratios (95% CI), p-value		Fully adjusted models^**, Hazard Ratios (95% CI), p-value
	GG (n=21,774)	GA + AA (n=8,302)	GG	GA + AA	GG	GA + AA	GG	GA + AA
CHD	1901	759	19.0	20.1	1.00	1.00 (0.91–1.09), p=0.94	1.00	1.01 (0.92–1.11), p=0.83
Stroke	970	373	9.6	9.7	1.00	1.11 (0.98–1.26), p=0.09	1.00	1.14 (1.00–1.30), p=0.06
Heart failure	1466	534	14.6	14.0	1.00	0.95 (0.86–1.05), p=0.33	1.00	0.99 (0.89–1.10), p=0.86
All-cause mortality	3115	1117	29.1	27.7	1.00	0.98 (0.91–1.05), p=0.59	1.00	1.00 (0.93–1.08), p=0.98
End stage renal disease	306	89	2.9	2.3	1.00	0.98 (0.76–1.25), p=0.87	1.00	0.95 (0.72–1.25), p=0.73

CHD = coronary heart disease

adjusted for age, sex, race, Hispanic status

^**

adjusted for age, sex, race, Hispanic status, baseline BMI, diabetes status, baseline LDL and HDL cholesterol, smoking status, baseline systolic and diastolic blood pressures, aspirin use